We are live on
!
Find out more
JJ
Johnson & Johnson Portfolio holdings
AUM
$799M
Turnover
17.65%
1-Year Est. Return
253.51%
This Fund
S&P 500
This Quarter
Est. Return
+10.76%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$427M
AUM Growth
+$26.7M
(+6.7%)
Cap. Flow
-$898K
Cap. Flow
% of AUM
-0.21%
Top 10 Holdings %
Top 10 Hldgs %
94.37%
Holding
21
New
1
Increased
–
Reduced
–
Closed
1
Avg Time Held
2.1
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clearside Biomedical
CLSD
|
+$93.9K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aldeyra Therapeutics
ALDX
|
+$992K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Protagonist Therapeutics
PTGX
$8.82B
| $110M | 25.79% |
2,449,183
| – | – |
2021 Q3
12 quarters
|
|
2
Rapport Therapeutics
RAPP
$1.36B
| $51.2M | 11.97% |
2,498,051
| – | – |
2024 Q2
1 quarter
|
|
3
Legend Biotech
LEGN
$3.7B
| $39.7M | 9.29% |
814,586
| – | – |
2021 Q3
12 quarters
|
|
4
Contineum Therapeutics
CTNM
$306M
| $37.9M | 8.86% |
1,979,173
| – | – |
2024 Q2
1 quarter
|
|
5
CVRx
CVRX
$35.7M
| $36.2M | 8.46% |
4,103,430
| – | – |
2021 Q3
12 quarters
|
|
6
Nanobiotix
NBTX
$1.08B
| $32.3M | 7.57% |
5,623,816
| – | – |
2023 Q3
4 quarters
|
|
7
Procept Biorobotics
PRCT
$1B
| $28.7M | 6.71% |
357,939
| – | – |
2021 Q3
12 quarters
|
|
8
MeiraGTx Holdings
MGTX
$904M
| $27.7M | 6.48% |
6,641,064
| – | – |
2021 Q3
12 quarters
|
|
9
Neumora Therapeutics
NMRA
$66.6M
| $24.4M | 5.72% |
1,849,445
| – | – |
2023 Q3
4 quarters
|
|
10
Xencor
XNCR
$1.74B
| $15M | 3.52% |
748,062
| – | – |
2021 Q4
11 quarters
|
|
11
Fate Therapeutics
FATE
$232M
| $11.8M | 2.77% |
3,379,064
| – | – |
2021 Q3
12 quarters
|
|
12
Arrowhead Research
ARWR
$8.25B
| $4.8M | 1.12% |
247,598
| – | – |
2021 Q3
12 quarters
|
|
13
Rallybio
RLYB
$89.8M
| $4.25M | 1% |
454,545
| – | – |
2024 Q2
1 quarter
|
|
14
Nano X Imaging
NNOX
$40.1M
| $966K | 0.23% |
158,852
| – | – |
2021 Q4
11 quarters
|
|
15
Vor Biopharma
VOR
$1.11B
| $752K | 0.18% |
53,733
| – | – |
2021 Q3
12 quarters
|
|
16
Standard BioTools
LAB
$248M
| $602K | 0.14% |
311,967
| – | – |
2024 Q1
2 quarters
|
|
17
Adicet Bio
ACET
$45.8M
| $525K | 0.12% |
22,780
| – | – |
2021 Q3
12 quarters
|
|
|
HLSQ
18
Tessera Defense and Homeland Security Inc.
HLSQ
$2.15M
| $196K | 0.05% |
1,012
| – | – |
2021 Q3
12 quarters
|
|
|
19
DELISTED
Clearside Biomedical
CLSD
| $105K | 0.02% |
+5,499
| New | +$93.9K |
2024 Q3
0 quarters
|
|
20
Senseonics Holdings Inc
SENS
$428M
| $19.1K | ﹤0.01% |
2,731
| – | – |
2021 Q3
12 quarters
|
|
|
21
Aldeyra Therapeutics
ALDX
$47.7M
| – | – |
-299,669
| Closed | -$992K | – |
|
Similar funds
SEM
TI
GIM
QCMNJ
LOPW
HW
CCM
LWM
Johnson & Johnson's Q3 2024 Portfolio in Review
As of Q3 2024, Johnson & Johnson held 21 positions worth $427M, up 6.7% from $401M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
Johnson & Johnson's Q3 2024 filing shows 1 new and 1 closed positions. Its largest new stake was Clearside Biomedical: 5,499 shares worth $105K. The largest sale was Aldeyra Therapeutics, an estimated $992K.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Johnson & Johnson's largest Q3 2024 buy was Clearside Biomedical: 5,499 shares worth $105K.
- Johnson & Johnson fully exited Aldeyra Therapeutics in Q3 2024, selling an estimated $992K.
- Johnson & Johnson's ten largest holdings make up 94% of its $427M portfolio in Q3 2024.
- Johnson & Johnson opened 1 new position and closed 1 in Q3 2024.
- Johnson & Johnson's portfolio value rose 6.7% quarter-over-quarter to $427M.
Based on Johnson & Johnson's 13F filing for Q3 2024, filed 13 Nov 2024.